

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM747460

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Eureka Therapeutics, Inc.		08/09/2022	Corporation:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	InvisiShield Technologies Ltd.		
<b>Street Address:</b>	5858 Horton Street, Suite 170		
<b>City:</b>	Emeryville		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94608		
<b>Entity Type:</b>	exempted company: CAYMAN ISLANDS		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90328357	INVISIMASK	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Email:</b>	tm_docket@iplg.com		
<b>Correspondent Name:</b>	Otto O. Lee		
<b>Address Line 1:</b>	1871 THE ALAMEDA, SUITE 250		
<b>Address Line 4:</b>	San Jose, CALIFORNIA 95126		
<b>NAME OF SUBMITTER:</b>	Otto O. Lee		
<b>SIGNATURE:</b>	/Otto O. Lee/		
<b>DATE SIGNED:</b>	08/10/2022		
<b>Total Attachments: 1</b>			
source=ETM-2022-01-US - Assignment_executed#page1.tif			

OP \$40.00 90328357

**TRADEMARK ASSIGNMENT**

WHEREAS, Eureka Therapeutics, Inc., a Delaware corporation having a principal business address at 5858 Horton St, Suite 170, Emeryville, CA 94608 ("Assignor"), has adopted and owns the trademark shown as follows ("the Mark"):

**INVISIMASK**

WHEREAS, Assignor applied to register the Mark on the Principal Register of the United States Patent and Trademark Office on November 18, 2020 under U.S. App. Serial No. 90328357 in connection with "Nasal spray preparations; Pharmaceutical preparations for the treatment and prevention of infectious diseases including viral and bacterial infections" in International Class 005:


WHEREAS, InvisiShield Technologies Ltd., a Cayman Islands exempted company having a principal business address at 5858 Horton St, Suite 170, Emeryville, CA 94608 ("Assignee"), desires to acquire the Mark and U.S. App. Serial No. 90328357;

WHEREAS, Assignee is a successor to the business of Assignor, or portion thereof, to which the Mark pertains, and that business is ongoing and existing.


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns, and transfers to Assignee all right, title, and interest in and to the Mark, together with the goodwill of the business symbolized by the Mark, and the portion of the business to which the Mark pertains, and U.S. App. Number 90328357.

This Agreement is entered into effect as of the date of full execution set forth below.

**Eureka Therapeutics, Inc.**

By:   
Name: CHENG LIU  
Title: CEO  
Date: 8/8/2022

**InvisiShield Technologies Ltd.**

By:   
Name: VINCENT SHAM  
Title: GENERAL COUNSEL  
Date: AUGUST 9, 2022